In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) in elderly patients with relapsed or unresponsive Hodgkin lymphoma (HL). This study found that this treatment was effective, although frail patients may be at higher risk for side effects. Some background Most patients with HL respond to front-line...
Read MoreCurrent treatment status-Undergoing active treatment-No response Posts on Medivizor
Reviewing treatment options for patients with recurrent classical Hodgkin’s lymphoma
In a nutshell This article reviews treatment options for patients with classical Hodgkin's lymphoma (cHL) that came back (relapsed) after chemotherapy. This study found that targeted therapies are becoming more prevalent and that patient outcomes have improved. Some background cHL is a cancer of white blood cells called lymphocytes....
Read MoreHave outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?
In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...
Read MoreThe comparison of outcomes of two salvage therapies in patients with relapsed or unresponsive acute myeloid leukemia
In a nutshell The study evaluated the effectiveness of two salvage therapies – mitoxantrone (Novantrone), etoposide (Etopophos), and cytarabine (Cytosar-U) also known as MEC and cladribine (Leustatin), cytarabine, filgrastim (Neupogen), and mitoxantrone also known as CLAG-M, for treating relapsed/refractory acute myeloid leukemia...
Read MoreEvaluating BEB chemotherapy for patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of BEB (busulfan, etoposide, bendamustine) chemotherapy for patients with non-Hodgkin’s lymphoma (NHL). This study found that BEB chemotherapy was effective and well-tolerated in these patients. Some background Autologous stem cell transplantation (ASCT) is a standard...
Read MoreIbrutinib as a salvage treatment after transplant for patients with chronic lymphocytic leukemia
In a nutshell This study aimed to investigate if ibrutinib was safe and effective as a salvage treatment after stem cell transplant in patients with chronic lymphocytic leukemia. This study concluded that ibrutinib is safe and effective as a salvage treatment in these patients. Some background Allogeneic...
Read MoreEvaluating stem cell transplant outcomes for patients classical Hodgkin’s lymphoma
In a nutshell This study looked at the outcomes of autologous stem cell transplantation (ASCT) to treat recurrent classical Hodgkin’s lymphoma (cHL). This study concluded that ASCT is effective, with patients who responded after the transplant having the best outcomes. Some background cHL is usually treated with chemotherapy and...
Read MoreEvaluating BEGEV chemotherapy before a stem cell transplant for hard-to-treat Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness of BEGEV chemotherapy for patients with relapsed or unresponsive Hodgkin lymphoma (HL) before a stem cell transplant. The authors concluded that this regimen was safe and effective for these patients. Some background Chemotherapy, followed by a stem cell transplant (SCT), remains the standard of...
Read MoreEvaluating long-term treatment with copanlisib for B-cell lymphoma
In a nutshell This looked at the safety and effectiveness of copanlisib (Aliqopa) for B-cell lymphoma that returned after previous treatment. This study found that long-term copanlisib treatment was safe and effective. Some background Indolent (painless) B-cell lymphoma is a slow-growing blood cancer. B-cell lymphoma that comes back or...
Read MoreEvaluating the combination of brentuximab vedotin and bendamustine in hard to treat Hodgkin lymphoma.
In a nutshell This study examined the safety and effectiveness of combining brentuximab vedotin (Adcetris) and bendamustine (Treanda) in patients with reoccurring or unresponsive Hodgkin lymphoma (HL). The authors concluded that this regimen shows promise in HL which is difficult to treat. Some...
Read MoreEvaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...
Read MoreMinimal residual disease status after inotuzumab ozogamicin in patients with relapsed/refractory acute lymphoblastic leukemia
In a nutshell This study aimed to investigate if minimal residual disease negativity is useful as a prognostic factor after inotuzumab ozogamicin treatment in patients with relapsed/refractory acute lymphoblastic leukemia. This study concluded minimal residual negativity with complete remission is associated with a better...
Read More
